[Federal Register Volume 61, Number 37 (Friday, February 23, 1996)]
[Notices]
[Pages 7008-7011]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-4067]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Advisory Committees; Notice of Meetings
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces forthcoming meetings of public advisory
committees of the Food and Drug Administration (FDA). This notice also
summarizes the procedures for the meetings and methods by which
interested persons may participate in open public hearings before FDA's
advisory committees.
FDA has established an Advisory Committee Information Hotline (the
hotline) using a voice-mail telephone system. The hotline provides the
public with access to the most current information on FDA advisory
committee meetings. The advisory committee hotline, which will
disseminate current information and information updates, can be
accessed by dialing 1-800-741-8138 or 301-443-0572. Each advisory
committee is assigned a 5-digit number. This 5-digit number will appear
in each individual notice of meeting. The hotline will enable the
public to obtain information about a particular advisory committee by
using the committee's 5-digit number. Information in the hotline
[[Page 7009]]
is preliminary and may change before a meeting is actually held. The
hotline will be updated when such changes are made.
MEETINGS: The following advisory committee meetings are announced:
General Hospital and Personal Use Devices Panel of the Medical
Devices Advisory Committee
Date, time, and place. March 11, 1996, 8 a.m., Holiday Inn--
Gaithersburg, Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.
A limited number of overnight accommodations have been reserved at the
hotel. Attendees requiring overnight accommodations may contact the
hotel at 301-948-8900 and reference the FDA Panel meeting block.
Reservations will be confirmed at the group rate based on availability.
Attendees with a disability requiring special accommodations should
contact Sociometrics, Inc., 301-608-2151. The availability of
appropriate accommodations cannot be assured unless prior notification
is received.
Type of meeting and contact person. Closed committee deliberations,
8 a.m. to 9 a.m.; open public hearing, 9 a.m. to 10 a.m., unless public
participation does not last that long; open committee discussion, 10
a.m. to 5 p.m.; Janet L. Scudiero, Center for Devices and Radiological
Health (HFZ-420), Food and Drug Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 301-594-1287, or FDA Advisory Committee
Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC
area), General Hospital and Personal Use Devices Panel, code 12520.
General function of the committee. The committee reviews and
evaluates data on the safety and effectiveness of marketed and
investigational devices and makes recommendations for their regulation.
Agenda--Open public hearing. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the committee. Those desiring to make formal presentations should
notify the contact person before March 4, 1996, and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time required to make their comments.
Open committee discussion. The committee will: (1) Discuss and make
recommendations on the classification of two unclassified preamendments
devices, percutaneously implanted long-term catheters, and implanted
intravascular infusion ports; and (2) discuss a premarket notification
submission for an antimicrobial coated latex examination glove.
Closed committee deliberations. FDA staff will present to the
committee trade secret and/or confidential commercial information
regarding present and future FDA issues. This portion of the meeting
will be closed to permit discussion of this information (5 U.S.C.
552b(c)(4)).
Joint Meeting of the Antiviral Drugs Advisory Committee and the
Dermatologic and Ophthalmic Drugs Advisory Committee (Ophthalmic
Drugs Subcommittee)
Date, time, and place. March 14, 1996, 1 p.m., and March 15, 1996,
8:30 a.m., Holiday Inn--Gaithersburg, Whetstone and Goshen Rooms, Two
Montgomery Village Ave., Gaithersburg, MD. -
Type of meeting and contact person. Closed committee deliberations,
March 14, 1996, 1 p.m. to 5 p.m.; open committee discussion, March 15,
1996, 8:30 a.m. to 11 a.m.; open public hearing, 11 a.m. to 12 m.,
unless public participation does not last that long; open committee
discussion, 12 m. to 4 p.m.; Ermona B. McGoodwin or Liz Ortuzar, Center
for Drug Evaluation and Research (HFD-21), Food and Drug
Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455,
or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), Antiviral Drugs Advisory Committee,
code 12531. -
General function of the committees. The Antiviral Drugs Advisory
Committee reviews and evaluates available data concerning the safety
and effectiveness of marketed and investigational human drug products
for use in the treatment of acquired immune deficiency syndrome (AIDS),
AIDS-related complex (ARC), and other viral, fungal, and mycobacterial
infections. The Dermatologic and Ophthalmic Drugs Advisory Committee
reviews and evaluates data concerning the safety and effectiveness of
marketed and investigational human drug products for use in the
treatment of dermatologic and ophthalmic disorders. -
Agenda--Open public hearing. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the committee. Those desiring to make formal presentations should
notify the contact person before March 8, 1996, and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time required to make their comments.-
Closed committee deliberations. On March 14, 1996, the Antiviral
Drugs Advisory Committee will discuss trade secret and/or confidential
commercial information relevant to pending new drug applications
(NDA's). This portion of the meeting will be closed to permit
discussion of this information (5 U.S.C. 552b(c)(4)). -
Open committee discussion. On March 15, 1996, the Antiviral Drugs
Advisory Committee and an ophthalmic drugs subcommittee of the
Dermatologic and Ophthalmic Drugs Advisory Committee will meet jointly
to discuss data relevant to NDA 20-638 VistideTM (cidofovir,
intravenous, Gilead Sciences, Inc.) for treatment of cytomegalovirus
(CMV) retinitis in patients with AIDS.
Blood Products Advisory Committee
Date, time, and place. March 21 and 22, 1996, 8 a.m., Holiday Inn--
Bethesda, Versailles Ballrooms II and III, 8120 Wisconsin Ave.,
Bethesda, MD.
Type of meeting and contact person. Open committee discussion,
March 21, 1996, 8 a.m. to 9:10 a.m.; open public hearing, 9:10 a.m. to
9:40 a.m., unless public participation does not last that long; open
committee discussion, 9:40 a.m. to 11:15 a.m.; open public hearing,
11:15 a.m. to 12:15 p.m., unless public participation does not last
that long; open committee discussion, 12:15 p.m. to 3 p.m.; open public
hearing, 3 p.m. to 4 p.m., unless public participation does not last
that long; open committee discussion, 4 p.m. to 5 p.m.; open committee
discussion, March 22, 1996, 8 a.m. to 11:30 a.m.; open public hearing,
11:30 a.m. to 12:15 p.m., unless public participation does not last
that long; open committee discussion, 12:15 p.m. to 2 p.m.; closed
committee deliberations, 2 p.m. to 3 p.m.; Linda A. Smallwood, Center
for Biologics Evaluation and Research (HFM-350), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-3514,
or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-
0572 in the Washington, DC area) Blood Products Advisory Committee,
code 12388.
General function of the committee. The committee reviews and
evaluates data on the safety and effectiveness, and appropriate use of
blood products intended for use in the diagnosis, prevention, or
treatment of human diseases.
Agenda--Open public hearing. Interested persons may present data,
[[Page 7010]]
information, or views, orally or in writing, on issues pending before
the committee. Those desiring to make formal presentations should
notify the contact person before March 15, 1996, and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time required to make their comments.
Open committee discussion. On March 21, 1996, the committee will
hear agency updates on Creutzfeldt-Jakob Disease and blood safety,
peripheral blood hematopoietic stem cell products intended for
transfusion, and a summary of regulatory issues related to human
reproductive tissue. Labeling issues regarding testing for antibody to
hepatitis C virus antigen by an ``HCV 3.0'' assay will be reviewed and
discussed in the morning and in the afternoon, there will also be a
discussion of clinical claims for the Roche Amplicor HIV Monitoring
TestTM. On March 22, 1996, the committee will review and discuss
implications of non-lipid enveloped viruses in blood products.
Closed committee deliberations. On March 22, 1996, the committee
will review trade secret and/or confidential commercial information
relevant to current and pending products. This portion of the meeting
will be closed to permit discussion of this information (5 U.S.C.
552b(c)(4)).
General and Plastic Surgery Devices Panel of the Medical Devices
Advisory Committee
Date, time, and place. March 25, 1996, 8:30 a.m., Holiday Inn--
Gaithersburg, Goshen Room, Two Montgomery Village Ave., Gaithersburg,
MD. A limited number of overnight accommodations have been reserved at
the hotel. Attendees requiring overnight accommodations may contact the
hotel at 301-948-8900 and reference the FDA Panel meeting block.
Reservations will be confirmed at the group rate based on availability.
Attendees with a disability requiring special accommodations should
contact John Sellman, Sociometrics, Inc., 301-608-2151. The
availability of appropriate accommodations cannot be assured unless
prior notification is received.
Type of meeting and contact person. Open public hearing, 8:30 a.m.
to 9:30 a.m., unless public participation does not last that long; open
committee discussion, 9:30 a.m. to 3 p.m.; closed committee
deliberations, 3 p.m. to 4:30 p.m.; Gail G. Gantt, Center for Devices
and Radiological Health (HFZ-410), Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850, 301-594-3090, or FDA Advisory
Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), General and Plastic Surgery Devices Panel, code
12519.-
General function of the committee. The committee reviews and
evaluates data on the safety and effectiveness of marketed and
investigational devices and makes recommendations for their
regulation.-
Agenda--Open public hearing. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the committee. Those desiring to make formal presentations should
notify the contact person before March 18, 1996, and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time required to make their comments.-
Open committee discussion. The committee will discuss and vote on a
premarket approval application for a resorbable translucent membrane
for use as an adjuvant in abdominopelvic surgery.
Closed committee deliberations. FDA staff will present to the
committee trade secret and/or confidential commercial information
regarding present and future FDA issues. This portion of the meeting
will be closed to permit discussion of this information (5 U.S.C.
552b(c)(4)).
Each public advisory committee meeting listed above may have as
many as four separable portions: (1) An open public hearing, (2) an
open committee discussion, (3) a closed presentation of data, and (4) a
closed committee deliberation. Every advisory committee meeting shall
have an open public hearing portion. Whether or not it also includes
any of the other three portions will depend upon the specific meeting
involved. The dates and times reserved for the separate portions of
each committee meeting are listed above.
The open public hearing portion of each meeting shall be at least 1
hour long unless public participation does not last that long. It is
emphasized, however, that the 1 hour time limit for an open public
hearing represents a minimum rather than a maximum time for public
participation, and an open public hearing may last for whatever longer
period the committee chairperson determines will facilitate the
committee's work.
Public hearings are subject to FDA's guideline (subpart C of 21 CFR
part 10) concerning the policy and procedures for electronic media
coverage of FDA's public administrative proceedings, including hearings
before public advisory committees under 21 CFR part 14. Under 21 CFR
10.205, representatives of the electronic media may be permitted,
subject to certain limitations, to videotape, film, or otherwise record
FDA's public administrative proceedings, including presentations by
participants.
Meetings of advisory committees shall be conducted, insofar as is
practical, in accordance with the agenda published in this Federal
Register notice. Changes in the agenda will be announced at the
beginning of the open portion of a meeting.
Any interested person who wishes to be assured of the right to make
an oral presentation at the open public hearing portion of a meeting
shall inform the contact person listed above, either orally or in
writing, prior to the meeting. Any person attending the hearing who
does not in advance of the meeting request an opportunity to speak will
be allowed to make an oral presentation at the hearing's conclusion, if
time permits, at the chairperson's discretion.
The agenda, the questions to be addressed by the committee, and a
current list of committee members will be available at the meeting
location on the day of the meeting.
Transcripts of the open portion of the meeting may be requested in
writing from the Freedom of Information Office (HFI-35), Food and Drug
Administration, rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857,
approximately 15 working days after the meeting, at a cost of 10 cents
per page. The transcript may be viewed at the Dockets Management Branch
(HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr.,
Rockville, MD 20857, approximately 15 working days after the meeting,
between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary
minutes of the open portion of the meeting may be requested in writing
from the Freedom of Information Office (address above) beginning
approximately 90 days after the meeting.
The Commissioner has determined for the reasons stated that those
portions of the advisory committee meetings so designated in this
notice shall be closed. The Federal Advisory Committee Act (FACA) (5
U.S.C. app. 2, 10(d)), permits such closed advisory committee meetings
in certain circumstances. Those portions of a meeting designated as
closed, however, shall be closed for
[[Page 7011]]
the shortest possible time, consistent with the intent of the cited
statutes.
The FACA, as amended, provides that a portion of a meeting may be
closed where the matter for discussion involves a trade secret;
commercial or financial information that is privileged or confidential;
information of a personal nature, disclosure of which would be a
clearly unwarranted invasion of personal privacy; investigatory files
compiled for law enforcement purposes; information the premature
disclosure of which would be likely to significantly frustrate
implementation of a proposed agency action; and information in certain
other instances not generally relevant to FDA matters.
Examples of portions of FDA advisory committee meetings that
ordinarily may be closed, where necessary and in accordance with FACA
criteria, include the review, discussion, and evaluation of drafts of
regulations or guidelines or similar preexisting internal agency
documents, but only if their premature disclosure is likely to
significantly frustrate implementation of proposed agency action;
review of trade secrets and confidential commercial or financial
information submitted to the agency; consideration of matters involving
investigatory files compiled for law enforcement purposes; and review
of matters, such as personnel records or individual patient records,
where disclosure would constitute a clearly unwarranted invasion of
personal privacy.
Examples of portions of FDA advisory committee meetings that
ordinarily shall not be closed include the review, discussion, and
evaluation of general preclinical and clinical test protocols and
procedures for a class of drugs or devices; consideration of labeling
requirements for a class of marketed drugs or devices; review of data
and information on specific investigational or marketed drugs and
devices that have previously been made public; presentation of any
other data or information that is not exempt from public disclosure
pursuant to the FACA, as amended; and, deliberation to formulate advice
and recommendations to the agency on matters that do not independently
justify closing.
This notice is issued under section 10(a)(1) and (2) of the Federal
Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR
part 14) on advisory committees.
Dated: February 15, 1996.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 96-4067 Filed 2-22-96; 8:45 am]
BILLING CODE 4160-01-F
